Quinn Opportunity Partners LLC Gilead Sciences, Inc. Transaction History

Quinn Opportunity Partners LLC

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$64.88 - $73.64 $583,920 - $662,760	-9,000 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$67.69 - $73.03 $676,900 - $730,300	-10,000 Reduced 52.63%	9,000 $629,000
Q2 2021 Aug 16, 2021	SELL	$63.47 - $69.35 $253,880 - $277,400	-4,000 Reduced 17.39%	19,000 $1.31 Million
Q1 2021 May 13, 2021	BUY	$60.0 - $68.46 $1.38 Million - $1.57 Million	23,000 New	23,000 $1.49 Million
Q1 2020 May 12, 2020	SELL	$62.63 - $80.22 $2.77 Million - $3.55 Million	-44,217 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$61.62 - $67.78 $246,480 - $271,120	4,000 Added 9.95%	44,217 $2.87 Million
Q3 2019 Nov 14, 2019	SELL	$62.51 - $69.0 $381,311 - $420,900	-6,100 Reduced 13.17%	40,217 $2.55 Million
Q2 2019 Aug 09, 2019	SELL	$61.87 - $69.38 $247,480 - $277,520	-4,000 Reduced 7.95%	46,317 $3.13 Million
Q1 2019 May 07, 2019	SELL	$62.53 - $70.05 $187,590 - $210,150	-3,000 Reduced 5.63%	50,317 $3.27 Million
Q4 2018 Feb 13, 2019	SELL	$60.54 - $79.0 $1.09 Million - $1.43 Million	-18,083 Reduced 25.33%	53,317 $3.34 Million
Q2 2018 Aug 14, 2018	BUY	$64.88 - $75.68 $648,800 - $756,800	10,000 Added 16.29%	71,400 $5.06 Million
Q1 2018 May 14, 2018	SELL	$72.84 - $88.8 $72,840 - $88,800	-1,000 Reduced 1.6%	61,400 $4.63 Million
Q4 2017 Feb 13, 2018	SELL	$71.15 - $83.52 $42,690 - $50,112	-600 Reduced 0.95%	62,400 $4.47 Million
Q3 2017 Nov 14, 2017	BUY	$72.11 - $85.47 $4.54 Million - $5.38 Million	63,000	63,000 $5.1 Million

1,927

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Quinn Opportunity Partners LLC, based on Form 13F filings with the SEC.

Stay updated on Quinn Opportunity Partners LLC with notifications on news.